deaths (OS)progression or deaths (PFS)RFS/DFS

squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) squamous cell - mNSCLC - L1 squamous - mNSCLC - L1 - all population

versus placebo plus SoC
ipilimumab plus SoC vs. placebo plus SoC 1 certainty unassessable-8% certainty unassessable-12%-